MX2017014911A - Fragmento fab de anticuerpo ngf anti-humano novedoso. - Google Patents

Fragmento fab de anticuerpo ngf anti-humano novedoso.

Info

Publication number
MX2017014911A
MX2017014911A MX2017014911A MX2017014911A MX2017014911A MX 2017014911 A MX2017014911 A MX 2017014911A MX 2017014911 A MX2017014911 A MX 2017014911A MX 2017014911 A MX2017014911 A MX 2017014911A MX 2017014911 A MX2017014911 A MX 2017014911A
Authority
MX
Mexico
Prior art keywords
human ngf
ngf antibody
fab fragment
antibody fab
fragment
Prior art date
Application number
MX2017014911A
Other languages
English (en)
Inventor
Fujita Hirotada
Tanaka Hirotsugu
Aoki Toshiaki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2017014911A publication Critical patent/MX2017014911A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona un fragmento Fab de anticuerpo NGF anti-humano superior, que mantiene una actividad de neutralización elevada y que reduce los efectos secundarios sistémicos resultantes de la exposición sistémica mientras expresa un efecto farmacológico local y medios para tratar el dolor postoperatorio utilizando dicho fragmento de anticuerpo. Un fragmento Fab de anticuerpo NGF anti-humano que comprende un fragmento de cadena pesada que consiste en la secuencia de aminoácidos que se representa en la SEC ID NO: 5 y una cadena ligera que consiste en la secuencia de aminoácidos que se representa en la SEC ID NO: 8.
MX2017014911A 2015-05-22 2016-05-20 Fragmento fab de anticuerpo ngf anti-humano novedoso. MX2017014911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015104806 2015-05-22
PCT/JP2016/065099 WO2016190263A1 (ja) 2015-05-22 2016-05-20 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント

Publications (1)

Publication Number Publication Date
MX2017014911A true MX2017014911A (es) 2018-03-23

Family

ID=57393503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014911A MX2017014911A (es) 2015-05-22 2016-05-20 Fragmento fab de anticuerpo ngf anti-humano novedoso.

Country Status (22)

Country Link
US (1) US11260124B2 (es)
EP (1) EP3299461B1 (es)
JP (1) JP6700620B2 (es)
KR (1) KR102440054B1 (es)
CN (1) CN107614683B (es)
AR (1) AR104721A1 (es)
AU (1) AU2016268625B2 (es)
BR (1) BR112017025029A2 (es)
CA (1) CA2986210C (es)
CO (1) CO2017012397A2 (es)
HK (1) HK1246349A1 (es)
IL (1) IL255832B (es)
MA (1) MA42138A (es)
MX (1) MX2017014911A (es)
MY (1) MY184164A (es)
PH (1) PH12017502126A1 (es)
RU (1) RU2729825C2 (es)
SG (1) SG11201709589XA (es)
TW (1) TWI706959B (es)
UA (1) UA123209C2 (es)
WO (1) WO2016190263A1 (es)
ZA (1) ZA201708169B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2904514T3 (es) * 2015-04-06 2022-04-05 Meso Scale Technologies Llc Sistema de alto rendimiento para realizar ensayos mediante el uso de electroquimioluminiscencia que incluye un aparato de agitación de consumibles
NL2017890B1 (nl) * 2016-11-29 2018-06-11 Josh Ip Iii B V Medische transportinrichting, hulpaandrijving, en werkwijze voor het transporteren van een dergelijke transportinrichting
US20210147529A1 (en) 2018-05-15 2021-05-20 Astellas Pharma Inc. Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527358A (en) 1994-01-21 1996-06-18 Medtronic, Inc. Temporary medical electrical lead
US20060147450A1 (en) 2002-10-04 2006-07-06 Shelton David L Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
ZA200504866B (en) 2002-12-24 2006-11-29 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
EP2364728A1 (en) 2003-07-15 2011-09-14 Amgen, Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR20060135060A (ko) * 2004-04-07 2006-12-28 리나트 뉴로사이언스 코퍼레이션 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US9315571B2 (en) 2005-01-24 2016-04-19 Elan Pharma International Limited Specific binding members for NGF
US9532943B2 (en) 2010-12-20 2017-01-03 Cormatrix Cardiovascular, Inc. Drug eluting patch for the treatment of localized tissue disease or defect
JP2007244601A (ja) 2006-03-15 2007-09-27 Kanazawa Univ 心筋用パッド
WO2009023540A1 (en) 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
JP4885308B2 (ja) 2009-03-19 2012-02-29 中外製薬株式会社 改良された抗体分子を含有する製剤
KR20120088550A (ko) 2009-05-04 2012-08-08 애보트 리서치 비.브이. 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
SG10201510484YA (en) 2010-12-20 2016-01-28 Cormatrix Cardiovascular Inc A drug eluting patch for the treatment of localized tissue disease or defect
BR112013028655B1 (pt) * 2011-05-06 2022-08-16 Zoetis Services Llc Anticorpos anti-fator de crescimento neuronal, composição farmacêutica compreendendo os mesmos e kit para o tratamento de dor em felinos
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
SG194795A1 (en) * 2011-05-06 2013-12-30 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
JP5376095B2 (ja) * 2011-08-11 2013-12-25 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
MX362394B (es) 2012-06-08 2019-01-15 Glenmark Pharmaceuticals Sa Anticuerpos anti-trka humanizados con sustituciones de aminoacidos.
JP6135161B2 (ja) 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) * 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
KR102506172B1 (ko) 2014-12-17 2023-03-07 다우 글로벌 테크놀로지스 엘엘씨 수성 폴리머 분산물을 갖는 점탄성 폴리우레탄 포옴

Also Published As

Publication number Publication date
CA2986210A1 (en) 2016-12-01
UA123209C2 (uk) 2021-03-03
AU2016268625A1 (en) 2017-12-07
CN107614683A (zh) 2018-01-19
CO2017012397A2 (es) 2018-02-28
MA42138A (fr) 2018-03-28
TWI706959B (zh) 2020-10-11
IL255832A (en) 2018-01-31
US11260124B2 (en) 2022-03-01
ZA201708169B (en) 2019-06-26
HK1246349A1 (zh) 2018-09-07
EP3299461A1 (en) 2018-03-28
EP3299461B1 (en) 2023-03-29
AR104721A1 (es) 2017-08-09
RU2017145071A (ru) 2019-06-24
MY184164A (en) 2021-03-24
EP3299461A4 (en) 2018-12-19
CA2986210C (en) 2022-04-26
RU2729825C2 (ru) 2020-08-12
JP6700620B2 (ja) 2020-05-27
PH12017502126A1 (en) 2018-05-07
US20180147281A1 (en) 2018-05-31
JPWO2016190263A1 (ja) 2018-04-12
IL255832B (en) 2021-07-29
RU2017145071A3 (es) 2019-10-17
SG11201709589XA (en) 2017-12-28
KR20180006391A (ko) 2018-01-17
TW201713691A (zh) 2017-04-16
WO2016190263A1 (ja) 2016-12-01
CN107614683B (zh) 2020-12-22
BR112017025029A2 (pt) 2018-08-07
KR102440054B1 (ko) 2022-09-06
AU2016268625B2 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
NZ738008A (en) Tigit-binding agents and uses thereof
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2015005252A (es) Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
MX2023006511A (es) Un anticuerpo monoclonal inhibidor del factor xiia.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
BR112018067897A2 (pt) imunoglobulinas modificadas com ligação de fcrn alterada
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX365899B (es) Composición farmacéutica que comprende un fragmento de péptido de hmgb1 para usarse en tratamiento de daño a la medula espinal.
SV2018005613A (es) Agentes, usos y metodos para el tratamiento
IL288728A (en) Anti-sortilin antibodies for use in therapy
MX2017014911A (es) Fragmento fab de anticuerpo ngf anti-humano novedoso.
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
IL278962A (en) Antibody against human TRL7
IL304200A (en) Combined treatment using anti-fucosyl-gm1 antibody
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
BR112016007816A2 (pt) composições peptídicas inovadoras
EP3778916A4 (en) PROCEDURE FOR ANTIGEN TREATMENT
AU2018341227A1 (en) Tissue factor-targeting CAR-NK and CAR-T cell therapy
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
WO2016135462A8 (en) Treatment
AR120054A1 (es) Politerapias con anticuerpos de cd-38